Philippe Rougier

发表

Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.

Sabine Tejpar, Volker Heinemann, Frank Beier, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Complete response of colorectal liver metastases after chemotherapy: does it mean cure?

Catherine Julié, Mostafa El Hajjam, Antoine Brouquet, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

Naotoshi Sugimoto, Yasuhiro Shimada, David Ferry, 2014, The Lancet. Oncology.

Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis.

Satoshi Morita, Yasuo Ohashi, Junichi Sakamoto, 2013, Journal of the National Cancer Institute.

Complete response of colorectal liver metastases after chemotherapy: does it mean cure?

Catherine Julié, Antoine Brouquet, Philippe Rougier, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Towards a pan-European consensus on the treatment of patients with colorectal liver metastases.

M. Ychou, E. Van Cutsem, B. Nordlinger, 2006, European journal of cancer.

Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer

Yasuo Ohashi, Junichi Sakamoto, Tomasz Burzykowski, 2009 .

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

Thomas Gruenberger, Laurence Collette, Peter M Schlag, 2008, The Lancet.

Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis.

Satoshi Morita, Yasuo Ohashi, Junichi Sakamoto, 2013, European journal of cancer.

Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.

Isabelle Salmon, Kathryn Graham, John R Mackey, 2012, Gastroenterology.

Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis.

Satoshi Morita, Yasuo Ohashi, Junichi Sakamoto, 2013, Journal of the National Cancer Institute.

Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial.

Pierre Michel, Bernard Denis, Pierre-Luc Etienne, 2011, The Lancet. Oncology.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Sabine Tejpar, Federico Cappuzzo, Mauro Delorenzi, 2010, The Lancet. Oncology.

Prognostic factors in primary gastrointestinal non‐Hodgkin's lymphoma. A multivariate analysis, report of 106 cases, and review of the literature

B. Caillou, P. Rougier, C. Théodore, 1989, Cancer.